| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.019 | 0.8 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.048 | 0.8 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.8 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | pandacostat | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.0094 | 0.8 |